Clear cell renal cell carcinoma (ccRCC) is the most common subtype of
renal carcinoma and is associated with poor prognosis and notorious for its immune dysfunction characteristic. SNRPA1 is a spliceosome component responsible for processing
pre-mRNA into
mRNA, while the biological effect of SNRPA1 in ccRCC remains elusive. The aim of this study was to decipher the effect of SNRPA1 on clinical effect and
tumor immunity for ccRCC patients. Multi-databases were collected to evaluate the different expression, prognostic value, DNA methylation,
tumor immune microenvironment, and drug sensitivity of SNRPA1 on ccRCC. IHC was utilized to validate the expression and prognostic value of SNRPA1 in ccRCC patients from the SMMU cohort. The knockout expression of SNRPA by sgRNA plasmid inhibited the cell proliferation, migration, and
metastasis ability and significantly increased the sensitivity of
sunitinib treatment. In addition, we explored the role of SNRPA1 in pan-
cancer level. The results indicated that SNRPA1 was differentially expressed in most
cancer types. SNRPA1 may significantly influence the prognosis of multiple
cancer types, especially in ccRCC patients. Notably, SNRPA1 was significantly correlated with immune cell infiltration and immune checkpoint inhibitory genes. In addition, the aggressive and immune inhibitory effects shown in SNRPA1 overexpression and the effect of SNRPA1 on ccRCC cell line invasion,
metastasis, and drug sensitivity in vitro were observed. Moreover, SNRPA1 was related to Myc, MTORC, G2M, E2F, and DNA repair pathways in various
cancer types. In all, SNRPA1 may prove to be a new
biomarker for prognostic prediction, effect
tumor immunity, and drug susceptibility in ccRCC.